Baby aspirin reduces liver fat in a small randomized trial.
Link to full study:
Paper · JAMA · 2024Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial.Conclusion: In this preliminary randomized clinical trial of patients with MASLD, 6 months of daily low-dose aspirin significantly reduced hepatic fat quantity compared with placebo. Further study in a larger sample size is necessary to confirm these findings.pmc.ncbi.nlm.nih.gov




